

## Number of patients with TEAEs reported with classification of the different organ systems

### Number of patients with TEAEs reported within the first 10 weeks after therapy start by SOC (SAF)

| Number of patients with at least one such event      | Eltrombopag<br>N=36 |      | Placebo<br>N=41 |      | Total<br>N=77 |      |
|--|---------------------|------|-----------------|------|---------------|------|
|  | N                   | %    | N               | %    | N             | %    |
| Total  | 31                  | 86.1 | 39              | 95.1 | 70            | 90.9 |
| Gastrointestinal disorders                           | 19                  | 52.8 | 25              | 61.0 | 44            | 57.1 |
| Nervous system disorders                             | 19                  | 52.8 | 24              | 58.5 | 43            | 55.8 |
| General disorders and administration site conditions | 13                  | 36.1 | 20              | 48.8 | 33            | 42.9 |
| Musculoskeletal and connective tissue disorders      | 12                  | 33.3 | 19              | 46.3 | 31            | 40.3 |
| Respiratory, thoracic and mediastinal disorders      | 11                  | 30.6 | 13              | 31.7 | 24            | 31.2 |
| Infections and infestations                          | 9                   | 25.0 | 13              | 31.7 | 22            | 28.6 |
| Skin and subcutaneous tissue disorders               | 8                   | 22.2 | 10              | 24.4 | 18            | 23.4 |
| Vascular disorders                                   | 8                   | 22.2 | 9               | 22.0 | 17            | 22.1 |
| Investigations                                       | 5                   | 13.9 | 6               | 14.6 | 11            | 14.3 |
| Hepatobiliary disorders                              | 9                   | 25.0 | 1               | 2.4  | 10            | 13.0 |
| Renal and urinary disorders                          | 4                   | 11.1 | 5               | 12.2 | 9             | 11.7 |
| Ear and labyrinth disorders                          | 4                   | 11.1 | 4               | 9.8  | 8             | 10.4 |
| Metabolism and nutrition disorders                   | 3                   | 8.3  | 5               | 12.2 | 8             | 10.4 |
| Eye disorders  | 5                   | 13.9 | 1               | 2.4  | 6             | 7.8  |
| Psychiatric disorders                                | 2                   | 5.6  | 4               | 9.8  | 6             | 7.8  |
| Cardiac disorders                                    | 2                   | 5.6  | 2               | 4.9  | 4             | 5.2  |
| Reproductive system and breast disorders             | 2                   | 5.6  | 2               | 4.9  | 4             | 5.2  |
| Blood and lymphatic system disorders                 | 1                   | 2.8  | 1               | 2.4  | 2             | 2.6  |
| Injury, poisoning and procedural complications       | 1                   | 2.8  | 0               | 0.0  | 1             | 1.3  |
| Surgical and medical procedures                      | 0                   | 0.0  | 1               | 2.4  | 1             | 1.3  |

**Number of patients with TEAEs reported between 10 weeks and 6 months after therapy start by SOC (SAF)**

| Number of subjects with at least one such event      | Eltrombopag<br>N=36 |      | Placebo<br>N=41 |      | Total<br>N=77 |      |
|--|---------------------|------|-----------------|------|---------------|------|
|  | N                   | %    | N               | %    | N             | %    |
| Total  | 30                  | 83.3 | 28              | 68.3 | 58            | 75.3 |
| Gastrointestinal disorders                           | 11                  | 30.6 | 16              | 39.0 | 27            | 35.1 |
| Skin and subcutaneous tissue disorders               | 10                  | 27.8 | 14              | 34.1 | 24            | 31.2 |
| Nervous system disorders                             | 10                  | 27.8 | 8               | 19.5 | 18            | 23.4 |
| Infections and infestations                          | 10                  | 27.8 | 6               | 14.6 | 16            | 20.8 |
| Investigations                                       | 5                   | 13.9 | 3               | 7.3  | 8             | 10.4 |
| Vascular disorders                                   | 3                   | 8.3  | 4               | 9.8  | 7             | 9.1  |
| General disorders and administration site conditions | 4                   | 11.1 | 2               | 4.9  | 6             | 7.8  |
| Musculoskeletal and connective tissue disorders      | 4                   | 11.1 | 2               | 4.9  | 6             | 7.8  |
| Respiratory, thoracic and mediastinal disorders      | 4                   | 11.1 | 2               | 4.9  | 6             | 7.8  |
| Cardiac disorders                                    | 2                   | 5.6  | 2               | 4.9  | 4             | 5.2  |
| Metabolism and nutrition disorders                   | 2                   | 5.6  | 2               | 4.9  | 4             | 5.2  |
| Hepatobiliary disorders                              | 2                   | 5.6  | 1               | 2.4  | 3             | 3.9  |
| Renal and urinary disorders                          | 1                   | 2.8  | 2               | 4.9  | 3             | 3.9  |
| Reproductive system and breast disorders             | 1                   | 2.8  | 2               | 4.9  | 3             | 3.9  |
| Blood and lymphatic system disorders                 | 1                   | 2.8  | 1               | 2.4  | 2             | 2.6  |
| Ear and labyrinth disorders                          | 0                   | 0.0  | 2               | 4.9  | 2             | 2.6  |
| Surgical and medical procedures                      | 0                   | 0.0  | 2               | 4.9  | 2             | 2.6  |
| Eye disorders  | 1                   | 2.8  | 0               | 0.0  | 1             | 1.3  |
| Immune system disorders                              | 0                   | 0.0  | 1               | 2.4  | 1             | 1.3  |
| Injury, poisoning and procedural complications       | 0                   | 0.0  | 1               | 2.4  | 1             | 1.3  |
| Psychiatric disorders                                | 0                   | 0.0  | 1               | 2.4  | 1             | 1.3  |